Barcelona 2022

Browse: Pre-Congress Content Sunday, 04.09.2022 Monday, 05.09.2022 Tuesday, 06.09.2022		Monday, 14.11.2022 Tuesday, 15.11.2022 Wednesday, 16.11.2022 Thursday, 17.11.2022 Friday, 18.11.2022

Citations should be made in the following way: Authors. Title. Eur Respir J 2022; 60: Suppl. 66, abstract number.

Beyond COVID: translating COVID treatment successes to all-cause ARDS

Hot topics
Chairs: M. Humbert (Le Kremlin-Bicêtre, France), J. Garcia Aymerich (Barcelona, Spain), M. Barrecheguren Fernandez (Barcelona, Spain)
Aims: To demonstrate that COVID ARDS may serve as model for all-cause ARDS, and to explain how COVID research data may help to improve the medical management of all-cause ARDS. The target audience includes translational and clinical scientists, as well as respiratory intensive care physicians. After the session, attendants will be able to identify the following: 1. how phenotypic data collected during the COVID pandemic will help distinguish ARDS phenotypes that are most likely to respond to treatment, 2. which of the treatments that were tested during the COVID pandemic are potential novel candidates for the treatment of ARDS, and 3. how research infrastructure developed in response to the COVID pandemic will help to accelerate drug development for ARDS.

Download all media

Translating COVID biomarkers to treatable traits in ARDS T. Jones (Philadelphia, United States)
Targeting novel pathways to dampen the inflammatory response M. Shankar-Hari (Edinburgh, United Kingdom)
Improving vascular stability to enhance alveolocapillary function in ARDS J. Aman (Amsterdam, Netherlands)
Adaptive platform trials: shifting gears from COVID to tailored ARDS interventions C. Calfee (San Francisco, United States)
Discussion and Q&A